We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Avadel Pharmaceuticals PLC | NASDAQ:AVDL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.52 | 2.84% | 18.82 | 18.51 | 19.10 | 19.09 | 17.9137 | 18.63 | 874,897 | 01:00:00 |
From May 2022 to May 2024
By Sabela Ojea
Avadel Pharmaceuticals PLC said Monday that its Lumryz narcolepsy treatment received final approval from the U.S. Food and Drug Administration to address excessive day-time sleepiness.
Shares rose 14% to $12.04 at 13:31 E.T.
The pharmaceutical company said Lumryz is a single dose at bedtime that treats narcolepsy in adults, a chronic neurological condition that effects about one in 2,000 people in the U.S.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 01, 2023 13:55 ET (17:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Avadel Pharmaceuticals Chart |
1 Month Avadel Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
